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The association of transcription corepressors SMRT and N-CoR with retinoid and thyroid receptors results in
suppression of basal transcriptional activity. A key event in nuclear receptor signaling is the
hormone-dependent release of corepressor and the recruitment of coactivator. Biochemical and structural
studies have identified a universal motif in coactivator proteins that mediates association with receptor LBDs.
We report here the identity of complementary acting signature motifs in SMRT and N-CoR that are sufficient
for receptor binding and ligand-induced release. Interestingly, the motif contains a hydrophobic core (FxxFF)
similar to that found in NR coactivators. Surprisingly, mutations in the amino acids that directly participate
in coactivator binding disrupt the corepressor association. These results indicate a direct mechanistic link
between activation and repression via competition for a common or at least partially overlapping binding site.
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Members of the steroid hormone receptor superfamily
are hormone-activated transcription factors that control
vertebrate development, differentiation, and homeosta-
sis through regulating complex gene networks (Man-
gelsdorf and Evans 1995; Mangelsdorf et al. 1995). Re-
ceptors for thyroid hormone and retinoid acid function
as potent repressors in the absence of ligand and as acti-
vators upon ligand binding. Intensive studies on the
mechanisms underlying this regulation led to the iden-
tification of different families of proteins that bind to the
receptors in the absence and presence of hormone.
SMRT (for silencing mediator for retinoid and thyroid
hormone receptors) and N-CoR (for nuclear receptor
corepressor) are homologous proteins that mediate the
repressive effect of unliganded nuclear receptors through
the recruitment of histone deacetylase complexes (Al-
land et al. 1997; Hassig et al. 1997; Heinzel et al. 1997;
Laherty et al. 1997; Nagy et al. 1997; Zhang et al. 1997).
In contrast, CBP/p300, p300/CBP-associated factor
(PCAF), and members of the p160 family (SRC-1; GRIP1/
TIF2; activator for thyroid hormones and retinoid recep-
tor (ACTR)/RAC3/P/CIP) (Onate et al. 1995; Hong et al.
1996; Kamei et al. 1996; Yao et al. 1996; Chen et al. 1997;
Torchia et al. 1997; Blanco et al. 1998) possess intrinsic
histone acetyl transferase activity and potentiate the
transcriptional activity of ligand bound receptors.
Nuclear receptors contain two evolutionarily con-
served modules, the DNA binding domain (DBD) and the
ligand binding domain (LBD). LBDs are required for
nuclear localization, homo- and/or heterodimerization,
and most importantly ligand binding and ligand-induced
switch of the transcriptional activity. Molecular studies
established that the LXXLL signature motif within co-
activators confers stereospecific interaction with ligand-
activated nuclear receptors (Heery et al. 1997). Biochemi-
cal and crystallographic analyses revealed that an LXXLL
motif-containing a-helix from coactivators interacts
with a hydrophobic groove within the ligand-bound
LBDs (Darimont et al. 1998; Nolte et al. 1998; Shiau et
al. 1998). Importantly, the residues that comprise the
hydrophobic groove are well conserved between nuclear
receptors and have long been recognized as an LBD sig-
nature motif.
Initial mapping studies with the corepressor proteins
revealed that the receptor interaction and repression
functions are separable (Chen and Evans 1995; Horlein et
al. 1995; Heinzel et al. 1997; Nagy et al. 1997), with the
receptor interaction domains located toward the car-
boxyl terminus. Ligand binding is thought to adopt con-
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formational changes that lead to release of the corepres-
sor and recruitment of the coactivators. However, the
molecular mechanism underlying this switch remains
unclear.
In this study we sought to characterize the molecular
basis for the interaction between nuclear receptors and
corepressors. We have identified in both SMRT and
N-CoR short peptides of 19 amino acids [interaction do-
main (ID) 1] and 17 amino acids (ID1), with an internal
signature motif (I/L)XX(I/V)I, which are sufficient for re-
ceptor interaction and ligand-induced dissociation. Se-
quence analyses suggest that these motifs can adopt an
amphipathic a-helical conformation, reminiscent of the
signature motif LXXLL within the coactivators. Signifi-
cantly, single mutations within the thyroid hormone re-
ceptor b (TRb) LBD known to be involved in coactivator
binding fail to bind corepressors. These results suggest
an underlying mechanistic link between coactivator and
corepressor binding via competition for a common or
overlapping binding site.
Results
Mapping of the core receptor interaction motifs
in SMRT
Previous studies have localized the receptor interaction
domains to the carboxyl terminus of SMRT and N-CoR.
Further studies of the SMRT receptor interaction region
revealed it could be subdivided into two domains of 70
and 50 amino acids (ID1 and ID2) (Fig. 1A; see also
Downes et al. 1996). Each of these domains can interact
with receptors when isolated from the rest of the protein.
Further examination of these two interacting domains
based on homology between N-CoR and SMRT, as well
as proteolysis studies of receptor corepressor complexes,
suggested that the minimal interaction core may be
smaller: 19 amino acids for ID2 and 17 amino acids for
ID1. Two-hybrid interaction assays were established in
mammalian cells in which Gal–DBD fusions of the
SMRT–ID1 and SMRT-ID2 were challenged with reti-
noic acid receptor a (RARa) fused to the VP16 activation
domain. As shown in Figure 1B, both the interaction
domains and the core motifs are sufficient to mediate
receptor corepressor interactions and ligand-mediated re-
lease in a fashion that mimics the full-length corepres-
sor. These peptides also function in yeast two-hybrid as-
says (Fig. 1C) suggesting that binding does not appear to
require additional accessory factors.
Mutations of the core hydrophobic residues
in interaction motifs abolish receptor interaction
Analysis of the sequences of the core motifs reveals that
each one contains a putative amphipathic a helix (Gar-
nier et al. 1978) (indicated by boldface underline, Fig. 2).
To test the idea that the hydrophobic surface of this po-
tential helix might form the critical surface for interac-
tion with the receptors, we mutated these residues and
tested, using the mammalian two-hybrid assay, their
ability to interact with RAR. Figure 2 shows that any
mutation of the core hydrophobic residues, either in
clusters (M1, M3, M10) or individually (M5–M7, M12–
M14), abolishes interaction of the corepressor with the
receptors. Interestingly, other mutations indicate that
the whole domain is generally sensitive to changes or
further truncations (Fig. 2, M8, M9, M15, and M16), sug-
Figure 1. Identification of minimal receptor in-
teraction domains in SMRT. (A) A schematic rep-
resentation of receptor interaction domains
within the corepressor SMRT domain structure
(sequence numbering corresponds to full-length
human SMRT). The interaction of the different
Gal–SMRT fusion constructs with RAR was
evaluated using both mammalian, CV1 (B) and
yeast (C) two-hybrid assays. Data were normal-
ized with reference to the activity of a constitu-
tive reporter. Transcriptional activity is ex-
pressed either as fold activation relative to
Gal–DBD alone (mammalian assay) or as report-
er activity (yeast). An RAR agonist at 10 nM
(TTNPB) was used in the mammalian assay to
demonstrate ligand-dependent corepressor re-
lease. Carboxyl-SMRT (C-SMRT) amino acids
2004–2517; (ID2) 2131–2201; (ID1) 2302–2352;
(core ID2) 2131–2149; (core ID1) 2336–2352
(numbering as in the full-length human SMRT).
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gesting that residues on the opposing surface of the helix
can still contribute to receptor binding.
In vitro analysis of the SMRT–ID : RAR–LBD :
RXR–LBD complexes
To demonstrate that these SMRT–ID motifs can interact
independently with receptors in vitro we assembled
complexes using bacterially expressed recombinant pro-
teins. Figure 3, A and B, shows gel filtration analyses
of stoichiometric complexes of the RAR–LBD : RXR
(retinoid X receptor)–LBD heterodimer alone and with
SMRT–ID1 and SMRT–ID2. In both cases, comparison of
the gel filtration profiles with known molecular mass
standards indicates a 1:1:1 stoichiometry and that the
complexes are stable and nonaggregating. This was sup-
ported by light scattering techniques, which indicated
that the samples were monodisperse with apparent mo-
lecular masses within 5 kD of that expected. In the case
of the RAR : RXR : SMRT–ID2 complex, equilibrium
analytical ultracentrifugation analyses indicated an
equilibrium between species up to a molecular mass >65
kD. Interestingly, the two SMRT receptor interaction
domains are significantly proteolysed unless copurified
in complex with the heterodimer (data not shown). This
suggests that they may be unstructured in the absence of
the unliganded receptor. This is analogous to the behav-
ior of coactivator receptor interaction domains that are
also unstructured in the absence of receptor but adopt a
helical conformation on binding (Nolte et al. 1998).
To characterize binding of the SMRT IDs to RAR :
RXR heterodimers, an in vitro binding and peptide com-
petition assay was established (Fig. 3E). We show that
[35S]methionine-labeled SMRT–ID2 binds to RAR : RXR
heterodimers. This binding is efficiently competed by
the addition of cold wild-type peptide at micromolar
concentrations (lanes 1–4). In contrast, peptides with
mutations in the core hydrophobic amino acids barely
compete, if at all (lanes M1–M4). This suggests that the
core IDs that we have identified are both necessary and
sufficient for RARa binding.
To test whether there is competition between coacti-
vator and corepressor binding to the receptor we estab-
lished an assay in which we could observe coactivator
binding in the absence of ligand. This was achieved by
using high concentrations of ACTR (immobilized on
GST resin) and RAR–LBD : RXR–LBD heterodimer. We
then asked how the presence of SMRT ID1 or ID2 con-
structs modulates the heterodimer–coactivator interac-
tion. Figure 3C shows a quantitative analysis of competi-
tive binding between coactivator and corepressor and in-
dicates that the addition of ligand allows restoration of
the ability of the heterodimer to interact with the coac-
tivator through the displacement of SMRT.
The identification of these motifs, which recapitulate
the behavior of the entire corepressor, suggests that we
have localized the critical determinants for corepressor
release. If this is the case, it would suggest that we might
be able to exploit these domains to create a chimeric
protein that can activate transcription in the absence of
ligand. Such a chimeric protein would reverse the nor-
mal signaling paradigm. We used this approach to exam-
ine the interaction between Gal–RAR and a fusion be-
tween SMRT–ID (1+2) and the VP16 activation domain
(Fig. 3F). Consistent with previous findings, we observed
that Gal–RAR alone represses transcription (lane 2). Ad-
Figure 2. Mutational analyses of the minimal interaction domains ID1, ID2, and ID(1+2). (A) Mutational analyses of SMRT–ID2; (B)
mutational studies of SMRT–ID1; (C) mutation studies of SMRT ID(1+2). The bar charts show reporter activity relative to wild-type
constructs. The horizontal lines indicate the extent of the helical regions predicted within ID1 and ID2. Mutants 1, 2, 3, 4, 10, 17, 18,
and 19 are in the context of longer SMRT constructs [(ID2) 2131–2201; (ID1) 2302–2352; (ID[1+2]) 2131–2352]. Mutants 5–9 and 12–16
are in the context of the core IDs [(core ID2) 2131–2149; (core ID1) 2336–2352].
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dition of VP–SMRT results in a large net activation of
transcription in the absence of ligand (lane 3). Addition
of ligand in this assay results in activation of the reporter
gene through the normal function of liganded RAR (lane
4). To prove that ligand can release the corepressor we
used an RXR helix 12 mutant (RXR-E > K,E > K). This
mutant has been shown previously to be defective in
transcriptional activation but not ligand binding (Schul-
man et al. 1997). In this case, unliganded receptor is
activated by VP–SMRT–ID (1+2) (lane 6). Addition of li-
gand leads to reversal of activation as a consequence of
SMRT–ID release (lane 7). These data emphasize that the
SMRT–IDs are necessary and sufficient for interaction
with receptors as well as ligand-dependent release.
Overlap of corepressor and coactivator binding sites
To address whether the same motif in SMRT–IDs is also
sufficient for TRb binding, we tested the interaction of
SMRT–IDs and TRb using the mammalian two-hybrid
assay. TRb interacts strongly with ID1 (Fig. 4A), and the
strength of interaction between TRb and the core ID1 is
comparable to that of the larger ID1 (50 amino acid) seg-
ment. Both full-length and core peptide show hormone-
induced dissociation (Fig. 4A). Significantly, single mu-
tations of the core hydrophobic residues within the ID1
core abolish interaction completely with TRb (Fig. 4B).
The finding that corepressor and coactivator binding mo-
tifs are both amphipathic a-helices suggests that they
may bind to similar or overlapping sites. The coactivator
motif LXXLL has been shown to bind to a hydrophobic
groove on the surface of the liganded receptor (Darimont
et al. 1998; Nolte et al. 1998; Shiau et al. 1998). To di-
rectly test whether corepressor interacts with the same
surface on the receptor as coactivators, we examined the
Figure 3. In vitro analysis of the SMRT–ID : RAR–LBD : RXR–LBD complexes. (A) Gel
filtration profiles of purified RAR–LBD : RXR–LBD heterodimers alone and with SMRT–
ID1 [(SID1) amino acids 2202–2352], SMRT–ID2 [(SID2) 2098–2201]. (B) SDS-PAGE cor-
responding to A. Fraction numbers are indicated below both the profiles and gels. Note
the relative elution volumes for the differently sized complexes. The heterodimer is
smallest and therefore retarded most by the column. In each case, the elution profile and
Coomassie staining in the gel are consistent with a 1:1:1 complex. This stoichiometry
was supported by equilibrium centrifugation and light-scattering techniques. (C) Ligand
facilitates the exchange of cofactors. The RAR agonist TTNPB increases the dissociation
of SMRT–IDs from the RAR : RXR : SID1 (hatched bars) and RAR : RXR : SID2 (solid
bars) complexes. This results in enhanced binding of RAR : RXR (open bars) to the
GST–ACTR–ID resin. (D) In vitro competition assay with SMRT–ID2 (arrowhead) wild-
type and mutant peptides. Radiolabeled ID2 was bound to GST–RXR–LBD : RAR–LBD
heterodimers as described in Materials and Methods. This complex was competitively
challenged by increasing the amount of wild-type synthetic peptide (lanes 1–4 using 0, 10, 30, and 100 µM peptide) or mutants 1–4
[M1–M4 at 30 µM (see Fig. 2)]. Quantitation of the wild-type competition assay is shown below. (E) (Left) SMRT minimal IDs can
mediate ligand-independent activation of RAR. (Lane 1) Gal–DBD alone; (lane 2) Gal–RAR alone; (lane 3) Gal–RAR + VP–SMRT
(ID1 + ID2); (lane 4) Gal–RAR + VP–SMRT (ID1 + ID2) + 10 nM TTNPB (RAR-specific agonist). (Right) Ligand-induced loss of activa-
tion of an RXR helix 12 mutant. (Lane 5) Gal–DBD alone; (lane 6) Gal–RXR mut (EK, EK) + VP–SMRT (ID1 + ID2); (lane 7) Gal–RXR
mut (EK, EK) + VP–SMRT (ID1 + ID2) + 100 nM LG268 (RXR-specific agonist).
Nagy et al.
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ability of various TRb mutants to interact with SMRT–
ID1 using the mammalian two-hybrid interaction assay.
We created point mutations in TRb that are known to
involve in coactivator binding. Residues V284, K288,
F293, Q301, and L305 are part of the groove that forms
the binding surface of the coactivators (Darimont et al.
1998). Specifically, V284 of H3, F293 of H4, and L305 of
H5 directly contact leucine residues of the signature mo-
tif LXXLL. Mutational studies with the previously de-
scribed helix 1 CoR box (Horlein et al. 1995) were not
considered because X-ray crystal structure clearly shows
that these mutants are buried in the RAR–LBD and could
not comprise a corepressor binding site (Wurtz et al.
1996). Figure 4C shows that mutations of these residues
also abolished interaction with corepressors. These data
indicate that these residues—284, 288, 293, 301, and
305—are critical for both coactivator and corepressor
binding, leading to the surprising suggestion that their
binding sites in the LBD must overlap partially.
Discussion
Perhaps the most important question concerning the
function of nuclear hormone receptors is how ligand fa-
Figure 4. Residues in human (h)TRb–LBD required
for coactivator interaction are also critical for core-
pressor binding. Mutational analysis of hTRb and
SMRT–ID1 was carried out using a mammalian two-
hybrid assay as described in Materials and Methods.
The strength of the interactions are expressed in
normalized promoter activity; the mean of three in-
dependent measurements ±S.E. is presented. (A) In-
teraction analysis of SMRT–ID1 with hTRb. The as-
says were carried out in the presence or absence of
100 nM T3. The core binding site (17 amino acids) of
SMRT–ID1 is sufficient for hTRb interaction. (B)
Mutations in the hydrophobic LXXII motif of SMRT
ID1 abolish hTRb interaction. Mutant residues of
the core motif are indicated. (C) Mutations in hTRb
required for coactivator interaction abolish corepres-
sor binding. Interaction analysis between the cor-
eRID and wild-type and mutant receptor LBDs were
carried out in the presence or absence of ligand (100
nM T3).
Nuclear receptor corepressor signature motif
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cilitates the switch from repression to activation of gene
expression. The first steps toward understanding the na-
ture of the repressed state came with the discovery of
two nuclear receptor corepressors (SMRT and N-CoR),
along with the demonstration that ligand causes core-
pressor dissociation while simultaneously promoting
the association of the coactivators (Chen and Evans
1995; Horlein et al. 1995). Significantly, both retinoid
and thyroid hormone receptors remain bound to their
target genes in both the repressive and active states. This
means that the switch in cofactor composition can be
made without dissociation of the regulatory complex.
Here we describe the identification and functional
analysis of the corepressor interaction motifs that medi-
ate recognition of unliganded receptors. Previous studies
have demonstrated that coactivators interact with
nuclear receptors via a short conserved association mo-
tif (Heery et al. 1997; Darimont et al. 1998; Nolte et al.
1998; Shiau et al. 1998). This work demonstrates that
there is a complementary structural basis for corepres-
sion. Two short autonomous motifs in the corepressors
are both necessary and sufficient for mediating corepres-
sor binding to unliganded receptors. Both motifs are able
to sense the presence of ligand by dissociating from the
receptor.
The two motifs, termed ID1 and ID2 (17 and 19 amino
acids, respectively), are conserved in both position and
sequence between N-CoR and SMRT. Secondary struc-
ture prediction suggests that they are likely to adopt an
amphipathic a-helical conformation. This further ex-
tends the analogy with the helical coactivator LXXLL
motifs. However, unlike the coactivators, it is clear that
additional flanking sequences are needed for the core-
pressor–receptor interaction. This suggests that the bind-
ing surface for corepressors is likely to be larger than that
for the coactivators.
Previous studies have suggested that mutations in the
AF-2 domain of RAR result in a receptor that is able to
bind ligand but is a constitutive repressor of gene expres-
sion (Chen et al. 1996b). Thus, ligand binding by itself is
not sufficient to induce dissociation of the corepressor.
Rather, it would appear that corepressor release requires
the receptor AF-2 domain. Because coactivator associa-
tion also requires the presence of the AF-2 domains,
these observations suggest mechanistic link between co-
repressor dissociation and coactivator binding. It has
been suggested previously (Chen et al. 1996b) that there
might be a competitive relationship between corepres-
sors and coactivators, possibly by recognition of a com-
mon or overlapping binding site. We investigated this
directly by mutating residues in the hydrophobic binding
pocket of the receptor that has been shown to accommo-
date the coactivator LXXLL motif (Darimont et al. 1998;
Nolte et al. 1998; Shiau et al. 1998). Remarkably, muta-
tions at five different sites within this pocket severely
disrupt corepressor binding.
Further support for there being overlapping binding
sites for corepressors and coactivators is provided
through the demonstration that under appropriate in
vitro conditions there is a direct competition between
coactivators and corepressors for the receptor’s binding
surface. It is clear, however, that under normal condi-
tions the presence or absence of ligand determines
whether coactivator or corepressor binding is favored.
The mechanism through which ligand discriminates be-
tween the two types of cofactor remains unclear. How-
ever, three observations suggest a plausible model: (1)
Coactivator binding requires a particular conformation
of helix 12; (2) corepressors can bind in the absence of
helix 12; and (3) helix 12 is required for ligand to induce
corepressor dissociation. Taken together, these findings
suggest that ligand-binding causes a conformational or
dynamic change in helix 12, resulting in the displace-
ment of corepressor and the formation of a suitable co-
activator binding surface. This in turn suggests that the
corepressor binding site may overlap not only the coac-
tivator binding site but also that of helix 12. This would
fit well with the observation that all three motifs are
capable of forming amphipathic a-helical conformations
(Fig. 5A). The model shown in Figure 5B is consistent
with our results here, as well as the work of Zhang et al
(1999), and also our previous suggestion that the AF-2
domain exists in a dynamic equilibrium between the ac-
Figure 5. Model for common biophysical mechanisms in co-
activator and corepressor interaction with nuclear receptors. (A)
Conserved amphipathic helices in corepressors, helix 12 of vari-
ous nuclear receptor, and the coactivator LXXLL motif. Helices
are aligned with hydrophobic residues shaded gray. (B) Potential
role of amphipatic helices in ligand-mediated switch of nuclear
receptor transcriptional activity.
Nagy et al.
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tive and the repressive conformational states (Schulman
et al. 1997).
In conclusion, the identification of a corepressor sig-
nature motif provides insight into the mechanism of re-
pressor recruitment, as well as suggesting a mechanism
whereby ligand-binding switches nuclear receptors from
transcriptional repressors to activators, thus explaining
the key feature of hormone signaling.
Materials and methods
Materials
Chemicals were purchased from Sigma (St Louis, MO) unless
indicated otherwise. The ligand LG100268 was the kind gift of
Richard A. Heyman (Ligand Pharmaceuticals, San Diego, CA).
TTNPB was purchased from Biomol, Inc. Mutations were gen-
erated by using the QuickChange kit (Stratagene, La Jolla,CA)
according to the manufacturer’s directions. Mutations were
verified by sequencing.
Transient transfection experiments in mammalian cells
and yeast transformations
Mammalian expression vectors used in this work have been
described previously (Chen and Evans 1995). Plasmids were con-
structed by standard cloning techniques. Detailed information
is available on request. CV1 cells were transiently transfected as
described previously (Chen and Evans 1995). Luciferase activity
of each sample was normalized with reference to the level of
b-galactosidase activity of a control reporter construct. Each
transfection was carried out in triplicate at least three times.
Percentage of maximal induction of the reporter gene or nor-
malized luciferase activity is presented as indicated in Figures
1B, 2, 3F, and 4. Yeast transfromation and b-galactosidase assays
were carried out according to the manufacturer’s instructions
(Clontech).
Gel filtration and competition assays
For the gel filtration assays histidine-tagged RAR–LBD and
RXR–LBD proteins were coexpressed in bacteria and purified as
described previously (Li et al. 1997). SMRT constructs were also
expressed using the T7 expression system. Protein complexes
were made by mixing resuspended cell pellets prior to lysis by
sonication in a buffer containing 50 mM HEPES (pH 8.0), 150
mM NaCl, 2.5 mM CaCl2, 20 mM imidazole, and 1 mM AEBSF
(Boehringer Mannheim/Melford). The histidine-tagged proteins
were bound to Ni–NTA agarose resin (Qiagen) and, after re-
peated washing, eluted using lysis buffer containing 250 mM
imidazole. Fractions containing the receptor or receptor–cofac-
tor complexes were pooled, concentrated (Amicon-stirred cell),
and further purified by anion exchange chromatography [200
mM NaCl elution from Poros PI resin (PE Biosystems)]. Com-
plexes were purified from excess components using a Superdex
S200 gel filtration column (Pharmacia).
For the competition assays, GST–RXR and His–RAR were
coexpressed as described previously (Li et al. 1997). The cells
were lysed by sonication and the heterodimer purified using
glutathione–Sepharose (Pharmacia) in buffer containing 50 mM
Tris (pH 8), 1% Triton X-100, and 1 mM AEBSF. [35S]methio-
nine-labeled SMRT–ID proteins were prepared by in vitro tran-
scription/translation (Promega). Peptides were either synthe-
sized in-house or purchased from Peptides Products or Genosys.
Competition assays were performed in buffer containing 50 mM
Tris (pH 7.4), 0.5% Triton X-100, and 1 mg/ml BSA. GST pull-
downs were performed using GST–RXR–LBD : RAR–LBD im-
mobilized on glutathione–Sepharose resin (Pharmacia). Gels
were quantitated using an image plate scanner (Molecular Dy-
namics).
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